{"id":"NCT00345579","sponsor":"GlaxoSmithKline","briefTitle":"Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age","officialTitle":"A Single-blind, Randomized, Controlled, Multinational Study for the Evaluation of Safety of GlaxoSmithKline (GSK) Biologicals' Investigational Vaccination Regimen Compared to Monovalent Haemophilus Influenzae Type b (Hib) Control Vaccine in Healthy Infants at 2, 4, 6, and 12 to 15 Months of Age.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-09","primaryCompletion":"2007-10","completion":"2008-03","firstPosted":"2006-06-28","resultsPosted":"2012-07-20","lastUpdate":"2016-12-16"},"enrollment":4432,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"PREVENTION"},"conditions":["Haemophilus Influenzae Type b","Neisseria Meningitidis"],"interventions":[{"type":"BIOLOGICAL","name":"GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined 792014","otherNames":[]},{"type":"BIOLOGICAL","name":"ActHIB","otherNames":[]},{"type":"BIOLOGICAL","name":"Pediarix/Infanrix Penta","otherNames":[]}],"arms":[{"label":"Menhibrix Group","type":"EXPERIMENTAL"},{"label":"ActHIB Group","type":"ACTIVE_COMPARATOR"}],"summary":"The primary phase of this study is evaluating the safety of Hib-MenCY-TT vaccine compared to a control group receiving licensed Hib conjugate vaccine, when each are co-administered with PediarixÂ® to healthy infants at 2, 4, and 6 months of age.\n\nThis protocol posting deals with objectives \\& outcome measures of the primary phase of the study. The objectives \\& outcome measures of the Booster phase are presented in a separate protocol posting (NCT number = 00345683).\n\nThe Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007","primaryOutcome":{"measure":"Number of Subjects Reporting Serious Adverse Events (SAEs)","timeFrame":"From Dose 1 up to Day 30 after Dose 3 (from study Month 0 up to study Month 5)","effectByArm":[{"arm":"MenHibrix Group","deltaMin":109,"sd":null},{"arm":"ActHIB Group","deltaMin":33,"sd":null}],"pValues":[]},"eligibility":{"minAge":"6 Weeks","sex":"ALL","healthyVolunteers":true,"inclusionCount":7,"exclusionCount":12},"locations":{"siteCount":63,"countries":["United States","Mexico"]},"refs":{"pmids":["21806393","22327493"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":157,"n":3278},"commonTop":[]}}